CN1234425C - 一种可吸收纤维蛋白止血贴的制备方法 - Google Patents
一种可吸收纤维蛋白止血贴的制备方法 Download PDFInfo
- Publication number
- CN1234425C CN1234425C CN 200410033680 CN200410033680A CN1234425C CN 1234425 C CN1234425 C CN 1234425C CN 200410033680 CN200410033680 CN 200410033680 CN 200410033680 A CN200410033680 A CN 200410033680A CN 1234425 C CN1234425 C CN 1234425C
- Authority
- CN
- China
- Prior art keywords
- hours
- hemostasis
- add
- preparation
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 10
- 108010073385 Fibrin Proteins 0.000 title description 7
- 102000009123 Fibrin Human genes 0.000 title description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title description 7
- 229950003499 fibrin Drugs 0.000 title description 7
- 230000002439 hemostatic effect Effects 0.000 title description 2
- 230000002745 absorbent Effects 0.000 title 1
- 239000002250 absorbent Substances 0.000 title 1
- 239000011505 plaster Substances 0.000 title 1
- 230000023597 hemostasis Effects 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 239000000725 suspension Substances 0.000 claims abstract description 25
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 23
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 23
- 108090000190 Thrombin Proteins 0.000 claims abstract description 21
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 21
- 229960004072 thrombin Drugs 0.000 claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004570 mortar (masonry) Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 238000009827 uniform distribution Methods 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 7
- 239000002245 particle Substances 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 48
- 239000000515 collagen sponge Substances 0.000 claims description 39
- 238000010792 warming Methods 0.000 claims description 32
- 239000000706 filtrate Substances 0.000 claims description 28
- 210000002435 tendon Anatomy 0.000 claims description 24
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 20
- 102000008186 Collagen Human genes 0.000 claims description 16
- 108010035532 Collagen Proteins 0.000 claims description 16
- 102000057297 Pepsin A Human genes 0.000 claims description 16
- 108090000284 Pepsin A Proteins 0.000 claims description 16
- 229920001436 collagen Polymers 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 16
- 229940111202 pepsin Drugs 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 13
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 10
- 239000011812 mixed powder Substances 0.000 claims description 10
- 229960002477 riboflavin Drugs 0.000 claims description 10
- 235000019192 riboflavin Nutrition 0.000 claims description 10
- 239000002151 riboflavin Substances 0.000 claims description 10
- 239000000835 fiber Substances 0.000 claims description 9
- 238000004821 distillation Methods 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 229960002588 cefradine Drugs 0.000 claims description 7
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 7
- 230000009514 concussion Effects 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 5
- 229940049954 penicillin Drugs 0.000 claims description 5
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 3
- NRVKJXFKQWUKCB-UHFFFAOYSA-N [2-[2-[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[5-[[1-[2-[4-[4-[3-(4-aminobutylamino)propylcarbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]ethylamino]-3-hydroxy-1-oxobutan-2-yl]amino]-3- Chemical compound Cl.N=1C(C=2SC=C(N=2)C(=O)NCCCNCCCCN)=CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C NRVKJXFKQWUKCB-UHFFFAOYSA-N 0.000 claims description 3
- 210000003141 lower extremity Anatomy 0.000 claims description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 3
- 229960004961 mechlorethamine Drugs 0.000 claims description 3
- 235000015277 pork Nutrition 0.000 claims description 3
- 230000001723 fibrinogenic effect Effects 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 abstract description 3
- 241001421714 Olynthus Species 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 230000008733 trauma Effects 0.000 abstract description 3
- 210000003462 vein Anatomy 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000000853 adhesive Substances 0.000 abstract 2
- 230000001070 adhesive effect Effects 0.000 abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 210000002565 arteriole Anatomy 0.000 abstract 1
- 230000004856 capillary permeability Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 102000034240 fibrous proteins Human genes 0.000 abstract 1
- 108091005899 fibrous proteins Proteins 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 238000004321 preservation Methods 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 229910017052 cobalt Inorganic materials 0.000 description 4
- 239000010941 cobalt Substances 0.000 description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010065441 Venous haemorrhage Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 238000013132 cardiothoracic surgery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410033680 CN1234425C (zh) | 2003-06-05 | 2004-04-16 | 一种可吸收纤维蛋白止血贴的制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03126762.9 | 2003-06-05 | ||
CNA031267629A CN1552465A (zh) | 2003-06-05 | 2003-06-05 | 纤维蛋白止血贴 |
CN 200410033680 CN1234425C (zh) | 2003-06-05 | 2004-04-16 | 一种可吸收纤维蛋白止血贴的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1602967A CN1602967A (zh) | 2005-04-06 |
CN1234425C true CN1234425C (zh) | 2006-01-04 |
Family
ID=34679641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410033680 Expired - Fee Related CN1234425C (zh) | 2003-06-05 | 2004-04-16 | 一种可吸收纤维蛋白止血贴的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1234425C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112972755B (zh) * | 2021-03-25 | 2022-07-05 | 哈尔滨瀚邦医疗科技有限公司 | 一种基于猪源纤维蛋白原和凝血酶的生物止血材料的制备方法 |
CN114177346B (zh) * | 2021-12-24 | 2023-05-26 | 中国人民解放军军事科学院军事医学研究院 | 一种止血组合物及止血贴与其应用 |
-
2004
- 2004-04-16 CN CN 200410033680 patent/CN1234425C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1602967A (zh) | 2005-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101455857B (zh) | 生物相容性变性淀粉海绵 | |
JP5883895B2 (ja) | 生物相容性の止血、癒着防止、癒合促進、外科密封可能な変性澱粉材料 | |
RU2193897C2 (ru) | Гемостатическая губка, основанная на коллагене, способ ее получения, повязка для ран, включающая такую губку, и набор для приготовления повязки для ран | |
CN102600013B (zh) | 一种医用植绒止血材料及其制备和应用 | |
US5643596A (en) | Hemostatic patch | |
Zheng et al. | Recent progress in surgical adhesives for biomedical applications | |
JP2011509932A5 (zh) | ||
CN101991875A (zh) | 介孔生物活性玻璃和壳聚糖复合多孔止血材料及制备方法 | |
JP2002513645A (ja) | 止血化合物および生体吸収性ポリマーを含む組成物 | |
KR20070046093A (ko) | 히알루론산을 포함하는 지혈 조성물 | |
CZ83194A3 (en) | Haemostatic preparation for inducing blood precipitation on a bleeding wound | |
CN105688265A (zh) | 一种可吸收止血材料及其制备方法和用途 | |
Mecwan et al. | Recent advances in biopolymer-based hemostatic materials | |
CN111954545A (zh) | 制备止血组合物的方法 | |
CN102580138A (zh) | 一种用于止血的多糖复合膜及其制备方法 | |
Irfan et al. | Gelatin-based hemostatic agents for medical and dental application at a glance: A narrative literature review | |
Guo et al. | Advances in the development and optimization strategies of the hemostatic biomaterials | |
US11357883B1 (en) | Method for preparing absorbable haemostatic composition for body and haemostatic composition prepared thereby | |
CN106975098B (zh) | 一种复合多糖止血组合物及其制备方法与应用 | |
CN113663120B (zh) | 止血海绵垫芯及其制备方法 | |
CN1234425C (zh) | 一种可吸收纤维蛋白止血贴的制备方法 | |
CN1552465A (zh) | 纤维蛋白止血贴 | |
CN106540310A (zh) | 一种可吸收性快速止血材料及其制备方法 | |
CZ277766B6 (en) | Biologically active material and process for preparing thereof | |
CN109157672A (zh) | 一种丝素-短肽凝血微球的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN QIYUANKANG BIOMEDICAL CO., LTD. Free format text: FORMER OWNER: HU QINGLIU Effective date: 20120418 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510515 GUANGZHOU, GUANGDONG PROVINCE TO: 518000 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120418 Address after: 518000 Shenzhen Guangming New District, Gongming Sixth Industrial Zone heshuikou xufa Science Park 6 layer A Patentee after: Shenzhen wonder biomedical Co., Ltd. Address before: 510515 Department of Tropical Hygiene and high temperature medicine, First Military Medical University, Guangdong, Guangzhou Patentee before: Hu Qingliu |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060104 Termination date: 20170416 |